Antitumor effects of human interferon-alpha 2b secreted by recombinant bacillus Calmette-Guérin vaccine on bladder cancer cells

Journal of Zhejiang University: Science B

Volumn 13, Issue 5, 2012, Pages 335-341

  Ding, Guo Qing ^a   Yu, Yan Lan ^a   Shen, Zhou Jun ^b   Zhou, Xie Lai ^a   Chen, Shan Wen ^a   Liao, Guo Dong ^a   Zhang, Yue ^c  

^a ZHEJIANG UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

Bacillus Calmette Gu rin (BCG) vaccine; Bladder neoplasms; Gene recombination; Interferon alpha 2b

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ALPHA2B INTERFERON; BCG VACCINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER CELL; BLOOD; CANCER CELL; CELL CULTURE; CELL PROLIFERATION; CYTOTOXICITY; ELECTROPORATION; ESCHERICHIA COLI; GENE SEQUENCE; GENOME; HUMAN; HUMAN CELL; IMMUNOGENICITY; MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECOMBINANT PLASMID; WILD TYPE;

APOPTOSIS; BCG VACCINE; CANCER VACCINES; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; INTERFERON-ALPHA; RECOMBINANT PROTEINS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; VIRAL VACCINES;

ESCHERICHIA COLI; MYCOBACTERIUM BOVIS BCG;

EID: 84863459270     PISSN: 16731581     EISSN: 18621783     Source Type: Journal    
DOI: 10.1631/jzus.B1100366     Document Type: Article

References (33)

1. Agarwal, A., Agrawal, U., Verma, S., Mohanty, N. K., Saxena, S., 2010. Serum Th1 and Th2 cytokine balance in patients of superficial transitional cell carcinoma of bladder pre-and post-intravesical combination immunotherapy. Immunopharmacol. Immunotoxicol., 32(2):348-356. [doi:10.3109/08923970903300151]
2. Alexandroff, A. B., Nicholson, S., Patel, P. M., Jackson, A. M., 2010. Recent advances in bacillus Calmette-Guerin immunotherapy in bladder cancer. Immunotherapy, 2(4):551-560. [doi:10.2217/imt.10.32]
3. Arnold, J., de Boer, E. C., O'Donnell, M. A., Böhle, A., Brandau, S., 2004. Immunotherapy of experimental bladder cancer with recombinant BCG expressing interferon-gamma. J. Immunother., 27(2):116-123. [doi:10.1097/ 00002371-200403000-00005] (Pubitemid 38282731)
4. Belldegrun, A. S., Franklin, J. R., O'Donnell, M. A., Gomella, L. G., Klein, E., Neri, R., Nseyo, U. O., Ratliff, T. L., Williams, R. D., 1998. Superficial bladder cancer: the role of interferon-alpha. J. Urol., 159(6):1793-1801. [doi:10. 1016/S0022-5347 (01) 63160-4] (Pubitemid 29190700)
5. Bowyer, L., Hall, R. R., Reading, J., Marsh, M. M., 1995. The persistence of bacille Calmette-Guerin in the bladder after intravesical treatment for bladder cancer. Br. J. Urol., 75(2):188-192. [doi:10.1111/j.1464-410X.1995. tb07309.x]
6. Chade, D. C., Borra, R. C., Nascimento, I. P., Villanova, F. E., Leite, L. C., Andrade, E., Srougi, M., Ramos, K. L., Andrade, P. M., 2008. Immunomodulatory effects of recombinant BCG expressing pertussis toxin on TNF-alpha and IL-10 in a bladder cancer model. J. Exp. Clin. Cancer Res., 27(1):78. [doi:10.1186/1756-9966-27-78]
7. de Boer, E. C., Rooijakkers, S. J., Schamhart, D. H., Kurth, K. H., 2003. Cytokine gene expression in a mouse model: the first instillations with viable bacillus Calmette-Guerin determine the succeeding Th1 response. J. Urol., 170(5):2004-2008. [doi:10.1097/01.ju.0000091826.83705.79] (Pubitemid 37254997)
8. Durek, C., Richter, E., Basteck, A., Rüsch-Gerdes, S., Gerdes, J., Jocham, D., Böhle, A., 2001. The fate of bacillus Calmette-Guerin after intravesical instillation. J. Urol., 165(5):1765-1768. [doi:10.1016/S0022-5347 (05) 66410-5] (Pubitemid 32410305)
9. Gakis, G., Todenhofer, T., Renninger, M., Schilling, D., Sievert, K. D., Schwentner, C., Stenzl, A., 2011. Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score. BJU Int., 108(11):1800-1805. [doi:10.1111/j.1464-410X. 2011.10234.x]
10. Hassen, W., Droller, M. J., 2000. Current concepts in assessment and treatment of bladder cancer. Curr. Opin. Urol., 10(4):291-299. [doi:10.1097/00042307-200007000-00002] (Pubitemid 30468191)
11. Lee, C. F., Chang, S. Y., Hsieh, D. S., Yu, D. S., 2004. Immunotherapy for bladder cancer using recombinant bacillus Calmette-Guerin DNA vaccines and interleukin-12 DNA vaccine. J. Urol., 171(3):1343-1347. [doi:10.1097/01.ju. 0000103924.93206.93]
12. Liu, W., O'Donnell, M. A., Chen, X., Han, R., Luo, Y., 2009. Recombinant bacillus Calmette-Guérin (BCG) expressing interferon-alpha 2b enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro. Cancer Immunol. Immunother., 58(10):1647-1655. [doi:10.1007/s00262-009-0673-z]
13. Luo, Y., Szilvasi, A., Chen, X., deWolf, W. C., O'Donnell, M. A., 1996. A novel method for monitoring Mycobacterium bovis BCG trafficking with recombinant BCG expressing green fluorescent protein. Clin. Diagn Lab. Immunol., 3(6):761-768. (Pubitemid 26388816)
14. Luo, Y., Chen, X., Han, R., O'Donnell, M. A., 2001. Recombinant bacille Calmette-Guérin (BCG) expressing human interferon-alpha 2b demonstrates enhanced immunogenicity. Clin. Exp. Immunol., 123(2):264-270. [doi:10. 1046/j.1365-2249.2001.01428.x] (Pubitemid 32174778)
15. Luo, Y., Yamada, H., Chen, X., Ryan, A. A., Evanoff, D. P., Triccas, J. A., O'Donnell, M. A., 2004. Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity. Clin. Exp. Immunol., 137(1):24-34. [doi:10.1111/j.1365- 2249.2004.02522.x] (Pubitemid 38869774)
16. Malmström, P. U., Sylvester, R. J., Crawford, D. E., Friedrich, M., Krege, S., Rintala, E., Solsona, E., di Stasi, S. M., Witjes, J. A., 2009. An individual patient data metaanalysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur. Urol., 56(2):247-256. [doi:10.1016/j.eururo.2009. 04.038]
17. Mohanty, N. K., Malhotra, V., Nayak, R. L., Arora, R. P., 2002. Combined low-dose intravesical immunotherapy (BCG+ interferon alpha-2b) in the management of superficial transitional cell carcinoma of the urinary bladder: a five-year follow-up. J. Chemother., 14(2):194-197. (Pubitemid 34454636)
18. Morales, A., Eidinger, D., Bruce, A. W., 1976. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J. Urol., 116(2):180-183.
19. Moro, A., Perea, S. E., Pantoja, C., Santos, A., Araña, M. D., Serrano, M., 2001. IFNalpha 2b induces apoptosis and proteasome-mediated degradation of p27Kip1 in a human lung cancer cell line. Oncol. Rep., 8(2):425-429. (Pubitemid 33758106)
20. O'Donnell, M. A., Lilli, K., Leopold, C., 2004. Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. J. Urol., 172(3):888-893. [doi:10.1097/01.ju.0000136446.37840.0a] (Pubitemid 39096415)
21. Pfeffer, L. M., Dinarello, C. A., Herberman, R. B., Williams, B. R., Borden, E. C., Bordens, R., Walter, M. R., Nagabhushan, T. L., Trotta, P. P., Pestka, S., 1998. Biological properties of recombinant α-interferons: 40th anniversary of the discovery of interferons. Cancer Res., 58(12):2489-2499. (Pubitemid 28275413)
22. Ratliff, T. L., 1992. Role of the immune response in BCG for bladder cancer. Eur. Urol., 21(S2):17-21.
23. Shahin, O., Thalmann, G. N., Rentsch, C., Mazzucchelli, L., Studer, U. E., 2003. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J. Urol., 169(1):96-100. [doi:10.1016/S0022-5347 (05) 64044-X] (Pubitemid 35461560)
24. Shelley, M. D., Mason, M. D., Kynaston, H., 2010. Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses. Cancer Treat. Rev., 36(3):195-205. [doi:10.1016/j.ctrv. 2009.12.005]
25. Shintani, Y., Sawada, Y., Inagaki, T., Kohjimoto, Y., Uekado, Y., Shinka, T., 2007. Intravesical instillation therapy with bacillus Calmette- Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy. Int. J. Urol., 14(2):140-146. [doi:10. 1111/j.1442-2042.2007.01696.x] (Pubitemid 46121952)
26. Suttmann, H., Jacobsen, M., Reiss, K., Jocham, D., Bohle, A., Brandau, S., 2004. Mechanisms of bacillus Calmette-Guerin mediated natural killer cell activation. J. Urol., 172(4):1490-1495. [doi:10.1097/01.ju.0000131944.52354.63] (Pubitemid 39249755)
27. van Der Meijden, A. P., Brausi, M., Zambon, V., Kirkels, W., de Balincourt, C., Sylvester, R., 2001. Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. J. Urol., 166(2):476-481. [doi:10.1016/S0022-5347 (05) 65966-6] (Pubitemid 32652226)
28. Varaldo, P. B., Leite, L. C., Dias, W. O., Miyaji, E. N., Torres, F. I., Gebara, V. C., Armôa, G. R., Campos, A. S., Matos, D. C., Winter, N., et al., 2004. Recombinant Mycobacterium bovis BCG expressing the Sm14 antigen of Schistosoma mansoni protects mice from cercarial challenge. Infect. Immun., 72(6):3336-3343. [doi:10.1128/IAI.72.6.3336-3343.2004] (Pubitemid 38697757)
29. Xu, Y., Liu, W., Shen, H., Yan, J., Qu, D., Wang, H., 2009. Recombinant Mycobacterium bovis BCG expressing the chimeric protein of antigen 85B and ESAT-6 enhances the Th1 cell-mediated response. Clin. Vaccine Immunol., 16(8):1121-1126. [doi:10.1128/CVI.00112-09]
30. Yalçinkaya, F., Kamis, L., Ozteke, O., Gunlusoy, B., Yigitbasi, O., Unal, S., 1998. Prospective randomized comparison of intravesical BCG therapy with standard dose versus low doses in superficial bladder cancer. Int. Urol. Nephrol., 30(1):41-44. [doi:10.1007/BF02550276] (Pubitemid 28458991)
31. Yamada, H., Matsumoto, S., Matsumoto, T., Yamada, T., Yamashita, U., 2000. Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2. J. Urol., 164(2):526-531. [doi:10.1016/S0022-5347 (05) 67417-4] (Pubitemid 30481978)
32. Yu, D. S., Lee, C. F., Chang, S. Y., 2007. Immunotherapy for orthotopic murine bladder cancer using bacillus Calmette-Guerin recombinant protein Mpt-64. J. Urol., 177(2):738-742. [doi:10.1016/j.juro.2006.09.074] (Pubitemid 46075126)
33. Zella, D., Barabitskaja, O., Casareto, L., Romerio, F., Secchiero, P., Reitz, M. S. Jr., Gallo, R. C., Weichold, F. F., 1999. Recombinant IFN-alpha (2b) increases the expression of apoptosis receptor CD95 and chemokine receptors CCR1 and CCR3 in monocytoid cells. J. Immunol., 163(6):3169-3175. (Pubitemid 29431816)